Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Gross Margin (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Gross Margin data on record, last reported at 53.37% in Q3 2025.

  • For Q3 2025, Gross Margin changed 0.0% year-over-year to 53.37%; the TTM value through Sep 2025 reached 57.54%, up 2167.0%, while the annual FY2024 figure was 54.46%, 1045.0% down from the prior year.
  • Gross Margin reached 53.37% in Q3 2025 per PLX's latest filing, down from 62.51% in the prior quarter.
  • Across five years, Gross Margin topped out at 82.47% in Q2 2023 and bottomed at 15.54% in Q4 2023.
  • Average Gross Margin over 5 years is 52.67%, with a median of 53.37% recorded in 2025.
  • Peak YoY movement for Gross Margin: crashed -5698bps in 2021, then skyrocketed 6312bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 63.18% in 2021, then increased by 14bps to 72.18% in 2022, then tumbled by -78bps to 15.54% in 2023, then surged by 406bps to 78.67% in 2024, then tumbled by -32bps to 53.37% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 53.37% in Q3 2025, 62.51% in Q2 2025, and 19.11% in Q1 2025.